StockData
AgomAb Therapeutics NV logo

AgomAb Therapeutics NV (AGMB) shareholders

AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.92−0.05 (-0.84%)

Close on Nov 17, 2026Market cap $148.00KP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
80.6%
28M of 34M shares
Institutional holders
34
9 new, 7 sold out
Net institutional buying
4M
In Q2 2026
Insider trades, 12 months
17 buys · 0 sales
Net bought $592.15K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
LSP 7 Cooperatieve U.A.
Joint filing with LSP 7 Management B.V. (10.60%)
5,141,99210.60%13D (active)Feb 9, 2026
Abigail P. Johnson
Joint filing with FMR LLC (10.00%)
4,873,68010.00%13G (passive)Feb 27, 2026
Tomer Kariv
Joint filing with Pontifax VI G.P. L.P. (6.80%), Pontifax Management 4 G.P. (2015) Ltd. (6.80%) and 1 more
3,305,8466.80%13G (passive)Mar 31, 2026
Sanofi2,783,0965.71%13G (passive)Mar 31, 2026
Redmile Group, LLC
Joint filing with Jeremy C. Green (5.60%), Redmile Biopharma Investments III, L.P. (5.60%)
2,735,9265.60%13G (passive)Mar 31, 2026
Bihua Chen
Joint filing with Cormorant Asset Management, LP (5.01%)
2,465,3485.01%13G (passive)Mar 31, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of AGMBValueChange% of portfolio
EQT Fund Management S.a r.l.5,141,99215.05%$66.74M–7.74%
Nantahala Capital Management, LLC3,136,3769.18%$40.71M+1,936,3760.68%
Sanofi2,783,0968.15%$36.12M–6.76%
Redmile Group, LLC2,733,9268.00%$35.49M+2,577,6762.38%
Cormorant Asset Management, LP2,465,3487.22%$32.00M–1.64%
TCG Crossover Management, LLC2,053,2336.01%$26.65M–0.64%
Federated Hermes, Inc.1,618,0004.74%$21.00M–0.03%
Casdin Capital, LLC1,550,0004.54%$20.12M–1.01%
Andera Partners1,538,7024.50%$19.97M–9.67%
FMR LLC1,458,6774.27%$18.93M–0.00%
abrdn plc846,6952.48%$10.99M+139,0390.02%
Perceptive Advisors LLC600,0001.76%$7.79M–0.12%
Samsara BioCapital, LLC600,0001.76%$7.79M–0.64%
Siren, L.L.C.411,2501.20%$5.34M–0.11%
Orbimed Advisors LLC192,7400.56%$2.50MNew0.05%
Pfizer Inc75,0000.22%$1.04M–0.61%
Alps Advisors Inc49,9840.15%$648.79KNew0.00%
Bellevue Group AG49,2480.14%$639.24K−7520.01%
Seven Grand Managers, LLC47,6000.14%$617.85K−152,4000.02%
Sectoral Asset Management Inc43,5000.13%$564.63K–0.39%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20263428M80.6%9 / 46 / 75M1M
Q1 20263223M68.4%32 / 00 / 023M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

FundShares% of AGMBValue% of fundAs of
Federated Hermes Kaufmann Fund981,1842.87%$12.63M0.26%Jul 31, 2026
Federated Hermes Kaufmann Small Cap Fund615,7081.80%$7.92M0.28%Jul 31, 2026
Fidelity Growth Company Fund507,8771.49%$5.71M0.01%May 31, 2026
Fidelity Growth Company K6 Fund141,3560.41%$1.59M0.01%May 31, 2026
Fidelity Series Growth Company Fund129,2000.38%$1.45M0.01%May 31, 2026
Federated Hermes Kaufmann Fund II21,1080.06%$273.98K0.24%Jun 30, 2026
Blackstone Alternative Multi-Strategy Fund17,6650.05%$229.29K0.01%Jun 30, 2026
Select Pharmaceuticals Portfolio9,1000.03%$102.38K0.01%May 31, 2026
Fidelity Nasdaq Composite Index Fund8,7460.03%$98.39K0.00%May 31, 2026
Steward Values Enhanced International Fund4,1090.01%$52.88K0.02%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Tim Jasper KnotnerusChief Executive Officer, Director56,2170.16%Oct 7, 2026
Pierre Thadee Victor KemulaChief Financial Officer10,0000.03%Oct 7, 2026
der Horst Paul Henryk vanChief Business Officer––Mar 18, 2026
Ellen LefeverGeneral Counsel––Mar 18, 2026
Andrea Saez BorderiasChief Development Officer––Mar 18, 2026
Philippe Constantin WieselChief Medical Officer––Mar 18, 2026
David R. EpsteinDirector54,9800.16%Nov 16, 2026
Marino GarciaDirector––Sep 15, 2026
Naimish PatelDirector––Sep 15, 2026
Ohad HammerDirector––Mar 18, 2026
Colin Michael BondDirector––Mar 18, 2026
Weegen Felice Isabel Verduyn-vanDirector––Mar 18, 2026
Angelika Martha JahreisDirector––Mar 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
David R. Epstein
Director
Nov 13, 2026Buy+4,960$6.02$29.86K54,980
David R. Epstein
Director
Nov 13, 2026Buy+5,000$5.75$28.75K50,020
David R. Epstein
Director
Nov 13, 2026Buy+20$6.00$12045,020
David R. Epstein
Director
Nov 13, 2026Buy+5,000$5.99$29.95K45,000
David R. Epstein
Director
Nov 5, 2026Buy+5,000$6.98$34.90K40,000
David R. Epstein
Director
Nov 5, 2026Buy+5,000$6.91$34.55K35,000
David R. Epstein
Director
Nov 5, 2026Buy+5,000$6.81$34.05K30,000
David R. Epstein
Director
Oct 21, 2026Buy+5,000$8.90$44.50K25,000
David R. Epstein
Director
Oct 21, 2026Buy+5,000$8.86$44.30K20,000
David R. Epstein
Director
Oct 8, 2026Buy+5,000$8.90$44.50K15,000
Tim Jasper Knotnerus
Chief Executive Officer, Director
Oct 6, 2026Buy+5,000$8.70$43.50K21,823
Pierre Thadee Victor Kemula
Chief Financial Officer
Oct 6, 2026Buy+2,000$8.54$17.08K10,000
Pierre Thadee Victor Kemula
Chief Financial Officer
Oct 6, 2026Buy+5,000$8.57$42.85K8,000
Pierre Thadee Victor Kemula
Chief Financial Officer
Oct 6, 2026Buy+3,000$8.67$26.01K3,000
David R. Epstein
Director
Oct 6, 2026Buy+5,000$8.70$43.50K10,000
Tim Jasper Knotnerus
Chief Executive Officer, Director
Oct 5, 2026Buy+6,000$8.48$50.88K16,823
David R. Epstein
Director
Oct 5, 2026Buy+5,000$8.57$42.85K5,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
1M shares short
Days to cover
7.4
At 0M shares a day
Change since last report
-2.2%
From 1M shares
Short volume, 20 days
12.7%
Of volume reported to FINRA

Shares sold short, last 9 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AgomAb Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 23,440 shares on Aug 21, 2026 over the last 90 days.

See a number that looks wrong?